Figure 6
Anti-SiglecH but not anti-PDCA treatment increase early lung Th17 frequency and inflammation. Mice were treated with anti-SiglecH and anti-PDCA as explained in the MATERIALS AND METHODS section. (a) The frequency of pDCs was evaluated in the lungs following treatment with anti-PDCA at 2 dpi. (b) The frequency of lung CD4+ CD44+ cells expressing IL-17 and/or IFNγ derived from mice treated with anti-SiglecH, anti-PDCA, or respective isotypes was determined at 2 dpi by flow cytometry. (c) The frequency of lung CD4+ CD44+ cells expressing IL-17 from mice treated with anti-SiglecH, anti-PDCA, or respective isotype at 2 and 5 dpi and expressed as the fold over respective isotype-treated mice. (d) H&E staining of lung sections from mice treated with anti-SiglecH, anti-PDCA, or respective isotype at 2 dpi. At least 100 fields were analyzed; scale bar=400 μm. (Bar graph represents average of three independent experiments. *P<0.05.) dpi, days post-infection; H&E, hematoxylin and eosin; IFN, interferon; IL, interleukin; NS, not statistically significant; pDCs, plasmacytoid dendritic cells; Th, T helper.
